Yahoo
OTC Markets OTCPK - Delayed Quote USD

Ion Beam Applications SA (IOBCF)

18.28 0.00 (0.00%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for IOBCF
  • Previous Close 18.28
  • Open 18.50
  • Bid 17.43 x 28100
  • Ask 18.82 x 10000
  • Day's Range 18.50 - 18.50
  • 52 Week Range 11.45 - 20.10
  • Volume 200
  • Avg. Volume 150
  • Market Cap (intraday) 530.855M
  • Beta (5Y Monthly) 1.26
  • PE Ratio (TTM) 19.24
  • EPS (TTM) 0.95
  • Earnings Date Aug 27, 2026
  • Forward Dividend & Yield 0.29 (1.56%)
  • Ex-Dividend Date Jun 15, 2026
  • 1y Target Est --

Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation and energy switching while the gantry is rotating; Proteus ONE, a compact proton therapy system transforming cancer treatment; Proteus PLUS, a proton therapy solution for cancer centers; and dosimetry solutions that includes radiation therapy; medical imaging; and QUASAR that offers a portfolio of sophisticated phantoms supporting MR guided radiation therapy, motion management, surface guided radiation therapy, geometric distortion analysis, and machine targeting solutions. It also offers radio pharma solutions, including radioisotopes, cyclotrons, and radiochemistry, as well as other integrated and industrial solutions, and services. In addition, the company is involved in construction of proton therapy, and other accelerators equipment and installation services; and operation and maintenance services, as well as sales a license for intellectual property. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

www.iba-worldwide.com

2,264

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is BEL 20 (^BFX) .

YTD Return

IOBCF
19.79%
BEL 20 (^BFX)
15.03%

1-Year Return

IOBCF
41.16%
BEL 20 (^BFX)
17.47%

3-Year Return

IOBCF
118.19%
BEL 20 (^BFX)
77.50%

5-Year Return

IOBCF
1.13%
BEL 20 (^BFX)
36.52%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY17
Revenue 65.69M
Earnings --
Profit Margin 0.00%

Q1

FY17

Q2

FY17

Q3

FY17

0
20M
40M
60M
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.85%

  • Return on Assets (ttm)

    3.67%

  • Return on Equity (ttm)

    20.66%

  • Revenue (ttm)

    639M

  • Net Income Avi to Common (ttm)

    24.61M

  • Diluted EPS (ttm)

    0.95

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    43.81M

  • Total Debt/Equity (mrq)

    99.65%

  • Levered Free Cash Flow (ttm)

    15.97M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: